Invitae (NYSE:NVTA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA) in a research report sent to investors on Friday morning. The firm issued a hold rating on the medical research company’s stock.

Invitae Price Performance

NVTA opened at $0.02 on Friday. Invitae has a twelve month low of $0.02 and a twelve month high of $0.02. The stock has a market capitalization of $5.21 million, a PE ratio of 0.00 and a beta of 1.59.

Institutional Trading of Invitae

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vestmark Advisory Solutions Inc. bought a new stake in shares of Invitae during the 4th quarter valued at about $526,000. Bourne Lent Asset Management Inc. lifted its holdings in shares of Invitae by 53.3% during the 4th quarter. Bourne Lent Asset Management Inc. now owns 574,600 shares of the medical research company’s stock worth $360,000 after acquiring an additional 199,900 shares during the last quarter. Green Alpha Advisors LLC grew its position in Invitae by 138.4% in the fourth quarter. Green Alpha Advisors LLC now owns 452,585 shares of the medical research company’s stock worth $284,000 after acquiring an additional 262,760 shares in the last quarter. Prosperity Wealth Management Inc. purchased a new position in Invitae in the fourth quarter worth $144,000. Finally, SG Americas Securities LLC increased its stake in Invitae by 90.7% in the fourth quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 43,717 shares during the last quarter. Institutional investors own 61.28% of the company’s stock.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.